Literature DB >> 22257021

A new strategy to stabilize oxytocin in aqueous solutions: II. Suppression of cysteine-mediated intermolecular reactions by a combination of divalent metal ions and citrate.

Christina Avanti1, Hjalmar P Permentier, Annie van Dam, Robert Poole, Wim Jiskoot, Henderik W Frijlink, Wouter L J Hinrichs.   

Abstract

A series of studies have been conducted to develop a heat-stable liquid oxytocin formulation. Oxytocin degradation products have been identified including citrate adducts formed in a formulation with citrate buffer. In a more recent study we have found that divalent metal salts in combination with citrate buffer strongly stabilize oxytocin in aqueous solutions (Avanti, C.; et al. AAPS J.2011, 13, 284-290). The aim of the present investigation was to identify various degradation products of oxytocin in citrate-buffered solution after thermal stress at a temperature of 70 °C for 5 days and the changes in degradation pattern in the presence of divalent metal ions. Degradation products of oxytocin in the citrate buffer formulation with and without divalent metal ions were analyzed using liquid chromatography-mass spectrometry/mass spectrometry (LC-MS/MS). In the presence of divalent metal ions, almost all degradation products, in particular citrate adduct, tri- and tetrasulfides, and dimers, were greatly reduced in intensity. No significant difference in the stabilizing effect was found among the divalent metal ions Ca(2+), Mg(2+), and Zn(2+). The suppressed degradation products all involve the cysteine residues. We therefore postulate that cysteine-mediated intermolecular reactions are suppressed by complex formation of the divalent metal ion and citrate with oxytocin, thereby inhibiting the formation of citrate adducts and reactions of the cysteine thiol group in oxytocin.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22257021     DOI: 10.1021/mp200622z

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  7 in total

Review 1.  Physicochemical and formulation developability assessment for therapeutic peptide delivery--a primer.

Authors:  Annette Bak; Dennis Leung; Stephanie E Barrett; Seth Forster; Ellen C Minnihan; Andrew W Leithead; James Cunningham; Nathalie Toussaint; Louis S Crocker
Journal:  AAPS J       Date:  2014-11-15       Impact factor: 4.009

2.  Rapid Absorption of Dry-Powder Intranasal Oxytocin.

Authors:  Mikolaj Milewski; Adrian Goodey; Dinah Lee; Eric Rimmer; Robert Saklatvala; Shuzo Koyama; Mic Iwashima; Shunji Haruta
Journal:  Pharm Res       Date:  2016-05-18       Impact factor: 4.200

Review 3.  Challenges for measuring oxytocin: The blind men and the elephant?

Authors:  Evan L MacLean; Steven Ray Wilson; W Lance Martin; John M Davis; Hossein P Nazarloo; C Sue Carter
Journal:  Psychoneuroendocrinology       Date:  2019-05-22       Impact factor: 4.905

4.  Heat-Stable Dry Powder Oxytocin Formulations for Delivery by Oral Inhalation.

Authors:  Karine Fabio; Kieran Curley; Joseph Guarneri; Benoit Adamo; Brendan Laurenzi; Marshall Grant; Robin Offord; Kelly Kraft; Andrea Leone-Bay
Journal:  AAPS PharmSciTech       Date:  2015-03-17       Impact factor: 3.246

5.  Development and stability of a heat-stable formulation of carbetocin for the prevention of postpartum haemorrhage for use in low and middle-income countries.

Authors:  Mattias Malm; Ingbritt Madsen; Johan Kjellström
Journal:  J Pept Sci       Date:  2018-04-27       Impact factor: 1.905

6.  Quality, availability and storage conditions of oxytocin and misoprostol in Malawi.

Authors:  Nhomsai Hagen; Felix Khuluza; Lutz Heide
Journal:  BMC Pregnancy Childbirth       Date:  2020-03-29       Impact factor: 3.007

7.  Stability of Oxytocin Preparations in Malawi and Rwanda: Stabilizing Effect of Chlorobutanol.

Authors:  Nhomsai Hagen; Thomas Bizimana; Pierre Claver Kayumba; Felix Khuluza; Lutz Heide
Journal:  Am J Trop Med Hyg       Date:  2020-11       Impact factor: 2.345

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.